Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers

Breast Cancer Research

Volumn 16, Issue 2, 2014, Pages

  Wendt, Michael K ^a   Taylor, Molly A ^b   Schiemann, Barbara J ^b   Sossey Alaoui, Khalid ^c   Schiemann, William P ^b  

^a PURDUE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BGJ 398; COMPLEMENTARY DNA; ESTROGEN RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBRONECTIN; IMMUNOGLOBULIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE INHIBITOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; 3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-(6-(4-(4-ETHYLPIPERAZIN-1-YL)-PHENYLAMINO)PYRIMIDIN-4-YL)-1-METHYLUREA; CADHERIN; CARBANILAMIDE DERIVATIVE; ISOPROTEIN; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ANIMAL CELL; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER INHIBITION; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ALTERNATIVE RNA SPLICING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CULTURE; CELL LINE; CYTOLOGY; DNA MICROARRAY; DRUG EFFECTS; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UDDER;

ALTERNATIVE SPLICING; ANIMALS; BREAST NEOPLASMS; CADHERINS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENYLUREA COMPOUNDS; PROTEIN ISOFORMS; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84897940136     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3623     Document Type: Article

References (41)

1. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y. Direct targeting of Sec23a by miR-200 s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011, 17:1101-1108. 10.1038/nm.2401, 3169707, 21822286.
2. Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell 2011, 22:2423-2435. 10.1091/mbc.E11-04-0306, 3135469, 21613543.
3. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007, 213:374-383. 10.1002/jcp.21223, 17680632.
4. Pinto CA, Widodo E, Waltham M, Thompson EW. Breast cancer stem cells and epithelial mesenchymal plasticity: implications for chemoresistance. Cancer Lett 2013, 341:56-62. 10.1016/j.canlet.2013.06.003, 23830804.
5. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010, 29:6485-6498. 10.1038/onc.2010.377, 3076082, 20802523.
6. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7:134. 10.1186/1471-2407-7-134, 1948892, 17650314.
7. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009, 115:115-121. 10.1007/s10549-008-0055-9, 18496750.
8. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 2008, 14:7878-7883. 10.1158/1078-0432.CCR-08-0141, 2748748, 19047117.
9. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007, 25:3816-3822. 10.1200/JCO.2006.09.6578, 17679728.
10. Madden SF, Clarke C, Aherne ST, Gaule P, O'Donovan N, Clynes M, Crown J, Gallagher WM. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res 2013, 15:R52. 10.1186/bcr3444, 23820017.
11. Johnson DE, Lu J, Chen H, Werner S, Williams LT. The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol 1991, 11:4627-4634. 361347, 1652059.
12. Werner S, Duan DSR, de Vries C, Peters KG, Johnson DE, Williams LT. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 1992, 12:82-88. 364071, 1309595.
13. Wang F, Kan M, Yan G, Xu J, McKeehan WL. Alternately spliced NH2-terminal immunoglobulin-like loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1. J Biol Chem 1995, 270:10231-10235. 10.1074/jbc.270.17.10231, 7730327.
14. Kalinina J, Dutta K, Ilghari D, Beenken A, Goetz R, Eliseenkova AV, Cowburn D, Mohammadi M. The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure 2012, 20:77-88. 10.1016/j.str.2011.10.022, 3378326, 22244757.
15. Luqmani YA, Mortimer C, Yiangou C, Johnston CL, Bansal GS, Sinnett D, Law M, Coombes RC. Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast. Int J Cancer 1995, 64:274-279. 10.1002/ijc.2910640411, 7657392.
16. Bruno IG, Jin W, Cote GJ. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet 2004, 13:2409-2420. 10.1093/hmg/ddh272, 15333583.
17. Shirakihara T, Horiguchi K, Miyazawa K, Ehata S, Shibata T, Morita I, Miyazono K, Saitoh M. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J 2011, 30:783-795. 10.1038/emboj.2010.351, 3041949, 21224849.
18. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 1996, 148:313-319. 1861604, 8546221.
19. Rak JW, McEachern D, Miller FR. Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia. Br J Cancer 1992, 65:641-648. 10.1038/bjc.1992.138, 1977372, 1586590.
20. Pink JJ, Bilimoria MM, Assikis J, Jordan VC. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer 1996, 74:1227-1236. A published erratum appears in Br J Cancer 1997, 75:1557, 10.1038/bjc.1996.521, 2075946, 8883409.
21. Wendt MK, Schiemann WP. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis. Breast Cancer Res 2009, 11:R68. 10.1186/bcr2360, 2790843, 19740433.
22. Hajra KM, Ji X, Fearon ER. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 1999, 18:7274-7279. 10.1038/sj.onc.1203336, 10602481.
23. Wendt MK, Smith JA, Schiemann WP. p130Cas is required for mammary tumor growth and transforming growth factor-β-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem 2009, 284:34145-34156. 10.1074/jbc.M109.023614, 2797185, 19822523.
24. Wendt MK. Identification of stable markers of the EMT:MET process. Published in Gene Expression Omnibus (GEO) database 30 January 2014 [GEO:GSE54491]. [http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54491].
25. Wendt MK, Schiemann BJ, Parvani JG, Lee YH, Kang Y, Schiemann WP. TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene 2013, 32:2005-2015. 10.1038/onc.2012.230, 3721373, 22710711.
26. Wendt MK, Molter J, Flask CA, Schiemann WP. In vivo dual substrate bioluminescent imaging. J Vis Exp 2011, 56:3245. 3227190, 22006228.
27. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 2010, 107:15449-15454. A published erratum appears in Proc Natl Acad Sci U S A 2010, 107:19132, 10.1073/pnas.1004900107, 2932589, 20713713.
28. Plasari G, Calabrese A, Dusserre Y, Gronostajski RM, McNair A, Michalik L, Mermod N. Nuclear factor I-C links platelet-derived growth factor and transforming growth factor β1 signaling to skin wound healing progression. Mol Cell Biol 2009, 29:6006-6017. 10.1128/MCB.01921-08, 2772573, 19752192.
29. Lee KY, Jeong JW, Wang J, Ma L, Martin JF, Tsai SY, Lydon JP, DeMayo FJ. Bmp2 is critical for the murine uterine decidual response. Mol Cell Biol 2007, 27:5468-5478. 10.1128/MCB.00342-07, 1952078, 17515606.
30. Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ, Yang J. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res 2011, 71:245-254. 10.1158/0008-5472.CAN-10-2330, 3025803, 21199805.
31. Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 2010, 70:5199-5202. A published erratum appears in Cancer Res 2010, 70:7734, 10.1158/0008-5472.CAN-10-0918, 20570901.
32. Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH, Hynes NE. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res 2013, 15:R8. 10.1186/bcr3379, 3672810, 23343422.
33. Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, Natrajan R, Reynolds AR, Reis-Filho JS, Ashworth A, Turner NC. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011, 17:5275-5286. 10.1158/1078-0432.CCR-10-2727, 3432447, 21712446.
34. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010, 70:4151-4162. 10.1158/0008-5472.CAN-09-4479, 20460524.
35. Shibue T, Weinberg RA. Integrin β1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A 2009, 106:10290-10295. Published errata appear in Proc Natl Acad Sci U S A 2009, 106:14734 and Proc Natl Acad Sci U S A 2014, 111:563, 10.1073/pnas.0904227106, 2700942, 19502425.
36. Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, Davis AS, Webster JD, Hoover S, Simpson RM, Gauldie J, Green JE. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res 2010, 70:5706-5716. 10.1158/0008-5472.CAN-09-2356, 3436125, 20570886.
37. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, Liu ZY, Costes SV, Cho EH, Lockett S, Khanna C, Chambers AF, Green JE. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 2008, 68:6241-6250. 10.1158/0008-5472.CAN-07-6849, 2561279, 18676848.
38. Zou L, Cao S, Kang N, Huebert RC, Shah VH. Fibronectin induces endothelial cell migration through β1-integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766. J Biol Chem 2012, 287:7190-7202. 10.1074/jbc.M111.304972, 3293564, 22247553.
39. Mori S, Wu CY, Yamaji S, Saegusa J, Shi B, Ma Z, Kuwabara Y, Lam KS, Isseroff RR, Takada YK, Takada Y. Direct binding of integrin αvβ3 to FGF1 plays a role in FGF1 signaling. J Biol Chem 2008, 283:18066-18075. 10.1074/jbc.M801213200, 2440593, 18441324.
40. Liang G, Chen G, Wei X, Zhao Y, Li X. Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev 2013, 24:467-475. 10.1016/j.cytogfr.2013.05.002, 23830577.
41. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-β. Future Oncol 2009, 5:1145-1168. 10.2217/fon.09.90, 2858056, 19852727.